Mabion (MAB) Company presentation summary

Company overview and strategy

• Over 17 years of experience in developing and manufacturing biological drugs, with comprehensive CDMO services and robust quality management systems certified by multiple authorities.

• Strategic transformation into a fully integrated CDMO focused on biologics, targeting small and medium-sized projects from early discovery to commercial production.

• Strong alignment with long-term biotech trends, including rising demand for biologics, especially monoclonal antibodies, and increasing outsourcing needs.

• Ongoing expansion with investments in new production facilities and technology upgrades, including the planned launch of Mabion II.

Service offering and client focus

• Provides a full spectrum of CDMO services, including process development, analytics, clinical and commercial manufacturing, and regulatory support.

• Well-positioned to serve clients from the EU, US, and select Asian markets, especially those requiring highly regulated manufacturing environments.

• Focuses on clients with recombinant protein-based products, particularly those using mammalian cell culture technologies.

Financial performance and achievements

• Achieved solid revenues and profitability for six consecutive quarters, with 2Q'24 EBITDA at 12.9 mln PLN and a margin of 43.2%.

• Maintained cost discipline despite inflationary pressures, with OPEX up 4.5% year-over-year mainly due to increased business development spending.

• Generated nearly 435 mln PLN in total revenues since 4Q'21, with 322 mln PLN from high-margin contract services.

• Strong operating cash flow in 1H'24 (+49.9 mln PLN), full repayment of bridge loan, and cash position of 50.2 mln PLN at period end.